Advanced Cell Technology (ACT) had already published 6-month data for the trial. The trial also showed evidence that the hearts of the patients that received the therapy showed less cardiac remodeling (an increase in the size of the heart that signifies worsening of function) than did control patients.
Principal investigator Dr Nabil Dib presented the results of the trial at the American Heart Association’s annual meeting in Orlando, Florida.
William Caldwell, IV, chairman and CEO of Advanced Cell Technology, said: “We are encouraged by the data Dr Dib presented from the results of our myoblast trial. The positive 12-month data presentation represents another step in our process of initiating a Phase II human clinical trial for our myoblast therapy. We look forward to moving the myoblast and other stem cell therapies through the clinic and ultimately to patients in need of treatment.”